<del>- 11-22-1-24</del>	· · · · · · · · · · · · · · · · · · ·			GP.164			
TRAN	TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))  Docketolo  P EEDAR 943453						
In Re Application Of: Keith L. Black and Nagendra S. Ningaraj							
		Filing Date 01/26/00	Examiner Unknown	roup Art Unit			
Title:	Method for U	Jsing Potassium Channel Agonists for l And/Or a Malignant	<del>-</del>	n Abnormal Region			
		ΔΑΑ	ress to:	APR 2 4 2000			
	Address to: Assistant Commissioner for Patents Washington, D.C. 20231		ssioner for Patents	TECH CENTER 1600/2900			
		37 CFF	R 1.97(b)	·			
	The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.						
		37 CFF	R 1.97(c)				
	The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:						
	1. a Final Action under 37 CFR 1.113, or						
•	2. a Notice of Allowance under 37 CFR 1.311,						
	whichever occurs first.						
	Also submitted herewith is:						
	☐ a certifi	cation as specified in 37 CFR 1.97(e)	);				
	OR						
		set forth in 37 CFR 1.17(p) for sult 7 CFR 1.97(c).	bmission of an Information	on Disclosure Statement			
		·					

TRANSMITTAL OF	Docket No.							
In Re Application Of:	Keith L. Black and Nagendra S. Ni	ngaraj	APR 2 1 2000 B					
Serial No.	Filing Date	Examiner	Group Unit					
09/491,500	01/26/00	Unknown	1646					
07/471,500 01/20/00 CHRHOWN								
Title:  Method for Using Potassium Channel Agonists for Delivering a Medicant to an Abnormal Region								
	And/Or a Malignar	nt Tumor	<b>A</b> n					
	, 01 uu		13. 149 2 V					
Method for Using Potassium Channel Agonists for Delivering a Medicant to an Abnormal Region  And/Or a Malignant Tumor  Payment of Fee  (Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))  A check in the amount of is attached.  The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. as described below. A duplicate copy of this sheet is enclosed.  Charge the amount of								
☐ Credit any	y overpayment.							
Charge any additional fee required.								
Certificate of	Transmission by Facsimile*	Certificate of Mail	ing by First Class Mail					
	ocument and authorization to charge ng facsimile transmitted to the United emark Office (Fax. No.	I certify that this document and fee is being deposited on 04/18/00 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.						
	Signature Signature of Person Mailing Correspondence							
	. =	An	nn Weiss					
Typed or Printed !	Name of Person Signing Certificate	Typed or Printed Name of	Person Mailing Correspondence					
*This certificate may only be used if paying by deposit account.  Dated: April 18, 2000  Signature  Nisan A. Steinberg, Ph.D. Registration No. 40,345  PRETTY, SCHROEDER & POPLAWSKI, P.C.  444 South Flower Street - 19th Floor Los Angeles, CA 90071-2909  Ofc: 213/622-7700  Fax: 213/489-4210								
cc:								

Copyright 1996 Legalsoft

P10A/REV01